{"id":2072,"date":"2015-03-10T14:51:36","date_gmt":"2015-03-10T06:51:36","guid":{"rendered":"http:\/\/www.appliedpsyj.org\/journal\/?p=2072"},"modified":"2015-03-11T16:48:55","modified_gmt":"2015-03-11T08:48:55","slug":"the-diagnosis-and-treatment-of-mild-cognitive-dementia-experiences-at-taipei-veterans-general-hospital","status":"publish","type":"post","link":"https:\/\/www.appliedpsyj.org.tw\/journal\/?p=2072","title":{"rendered":"The Diagnosis and Treatment of Mild Cognitive Dementia: Experiences at Taipei Veterans General Hospital"},"content":{"rendered":"

Pei-Ning Wang<\/strong>
\nDepartment of Neurology, School of medicine, National Yang-Ming University, Department of Neurology, Taipei Veterans General Hospital
\nKer-Neng Lin<\/strong>
\nDepartment of Psychology, Soo-Chow University, Department of Neurology, Taipei Veterans General Hospital
\nHsiu-Chih Liu<\/strong>
\nDepartment of Neurology, National Yang-Ming University, Department of Neurology, Taipei Veterans General Hospital<\/p>\n

Mild cognitive impairment (MCI) is a transitional state between normal cognition and mild dementia. Although some MCI patients return back to normal cognition, most MCI progress to dementia. The dementia research group in Taipei Veterans General Hospital has conducted several prospective studies to evaluate the manifestation of amnestic MCI and the outcomes of patients who develop the disease. Patients with amnestic MCI experience levels of performance in memory and daily function that range between normal elderly and mild Alzheimer\u2019s disease (AD) dementia patients. The hippocampal volume and annual atrophy rates of hippocampus in patients with amnestic MCI also range between normal elderly and mild AD dementia patients. Apolipoprotien E \u03f5 4 may increase the risk and shorten the duration of the progression from amnestic MCI to AD dementia. Integrating the present evidence from literature and our research, the clinical, genetic and neuroimaging features of amnestic MCI appear very similar to very early A D. The 2011 diagnostic criteria for MCI suggest diagnosing MCI patients coexisting with AD biomarkers as MCI due to AD. This new criteria emphasize the evidence suggesting that MCI with AD biomarkers may actually be the very early stages of AD. Until now, there is no proved pharmacological treatment for MCI. However, we may decelerate the progression from MCI to dementia by controlling the risk factors and cognitive training. Early diagnosis and early treatment is the best therapy for dementia.<\/p>\n

Keywords: mild cognitive impairment, very early dementia, Alzheimer\u2019s disease,cognition, apolipoprotein E<\/p>\n","protected":false},"excerpt":{"rendered":"

Pei-Ning Wang Department of Neurology, School of medici …<\/span> Read More →<\/span><\/a><\/span><\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[144],"tags":[],"class_list":["post-2072","post","type-post","status-publish","format-standard","hentry","category-144"],"aioseo_notices":[],"aioseo_head":"\n\t\t\n\t\n\t\n\t\n\t\n\t\n\t\t\n\t\t\n\t\t\n\t\t\n\t\t\n\t\t\n\t\t\n\t\t\n\t\t\n\t\t\n\t\t\n\t\t